RxDoctor Payments Data

Purnell Kirkland, MD

Rheumatology · Inglewood, CANPI 1629133368

Payments from drug & device makers

$2,261in general payments, 2019–2025

Across 43 payments — averaging $52.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Scientific Affairs, LLC$1K
  • Johnson & Johnson$387
  • Amgen$283
  • GSK$106
  • Boehringer Ingelheim$96
  • Portola Pharmaceuticals, LLC$63
  • plus $95 from 3 others

What the payments were for

  • Consulting fees$1,08048%
  • Food & beverage$1,18152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,261 in reported general payments places this provider in the 50th percentile of 808 rheumatology providers in California.

See all rheumatology providers in California

Medicare billing

Part B allowed, 2024
$86,783
Medicare patients
56
Services billed
24,382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrenciaAbatacept66$372,277
Enbrel SureclickEtanercept22$155,689
BenlystaBelimumab25$116,234
EliquisApixaban42$17,184
Hydroxychloroquine Sulfate379$10,970
JanuviaSitagliptin Phosphate15$8,110
MethotrexateMethotrexate Sodium385$6,388
Celecoxib155$6,024
Dexlansoprazole DrDexlansoprazole14$4,592
Diclofenac Sodium330$3,123
Prednisone459$2,038
Leflunomide40$1,418
Diclofenac Sodium ErDiclofenac Sodium43$1,216
Pregabalin80$1,083
Bupropion XlBupropion Hcl107$994

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBenlysta$106$116,23425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 808 rheumatology providers in California.

Other rheumatology in Inglewood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →